Petr Vladimirovich Kruglyakov
Vorstandsvorsitzender bei PHARMSYNTHEZ
Profil
Petr Vladimirovich Kruglyakov is currently the Director General at Pharmsynthez PJSC.
He previously worked as the Director-Research & Development at Artgen Biotech PJSC from 2010 to 2011 and as the Executive Director at SynBio LLC from 2013 to 2014.
Dr. Kruglyakov obtained his undergraduate degree from the State University of St. Petersburg.
Aktive Positionen von Petr Vladimirovich Kruglyakov
| Unternehmen | Position | Beginn |
|---|---|---|
| PHARMSYNTHEZ | Vorstandsvorsitzender | 01.01.2014 |
Ehemalige bekannte Positionen von Petr Vladimirovich Kruglyakov
| Unternehmen | Position | Ende |
|---|---|---|
SynBio LLC
 SynBio LLC Pharmaceuticals: MajorHealth Technology SynBio LLC engages in original research and introduction of conceptually new medicines. The firm’s medicines help treat diseases like liver disease, cardiovascular disease, acute leukemia, growth hormone deficiency and diabetes milletus. Its work is based on scientific developments and conducted in cutting edge laboratories. The company was founded in 2011 and is headquartered in Moscow, Russian Federation. | Vorstandsvorsitzender | 01.01.2013 |
| HUMAN STEM CELLS INSTITUTE | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2011 |
Ausbildung von Petr Vladimirovich Kruglyakov
| State University of St. Petersburg | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| HUMAN STEM CELLS INSTITUTE | Health Services |
| PHARMSYNTHEZ | Health Technology |
| Private Unternehmen | 1 |
|---|---|
SynBio LLC
SynBio LLC Pharmaceuticals: MajorHealth Technology SynBio LLC engages in original research and introduction of conceptually new medicines. The firm’s medicines help treat diseases like liver disease, cardiovascular disease, acute leukemia, growth hormone deficiency and diabetes milletus. Its work is based on scientific developments and conducted in cutting edge laboratories. The company was founded in 2011 and is headquartered in Moscow, Russian Federation. | Health Technology |